StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM
Credit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).Analyst Vamil ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Downgrades
Next Articles
Teva Pharma (TEVA) Granted FDA Approval of QVAR® RediHaler (Beclomethasone Dipropionate HFA) Inhalation Aerosol
August 7, 2017 8:01 AM
Teva Pharma (TEVA) PT Lowered to $28 at Deutsche Bank
August 4, 2017 8:41 AM
Teva Pharma (TEVA) PT Lowered to $26 at Jefferies
August 4, 2017 7:50 AM
RBC Capital Double Downgrades Teva Pharma (TEVA) to Underperform
August 4, 2017 5:54 AM
Cowen Downgrades Teva Pharma (TEVA) to Market Perform
August 4, 2017 5:51 AM
Teva Pharma (TEVA) PT Lowered to $23 at Piper Jaffray, Lowers EPS Estimates
August 3, 2017 2:37 PM
Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald
August 3, 2017 12:51 PM
Teva Pharma (TEVA) Sinks 16% on Weak Results, Outlook
August 3, 2017 8:18 AM
Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield
August 3, 2017 6:35 AM
Teva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend
August 3, 2017 6:33 AM
